Precigen Gestione
Criteri Gestione verificati 4/4
Precigen Il CEO è Helen Sabzevari, nominato in Jan2020, e ha un mandato di 6.58 anni. la retribuzione annua totale è $ 5.35M, composta da 18.7% di stipendio e 81.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.05% delle azioni della società, per un valore di $ 27.25M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.6 anni e 12.3 anni.
Informazioni chiave
Helen Sabzevari
Amministratore delegato
US$5.4m
Compenso totale
| Percentuale dello stipendio del CEO | 18.68% |
| Mandato del CEO | 6.6yrs |
| Proprietà del CEO | 1.1% |
| Durata media del management | 6.6yrs |
| Durata media del Consiglio di amministrazione | 12.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement
Summary Precigen, Inc. is upgraded to a Strong Buy, driven by surging PAPZIMEOS revenues and FDA approval for recurrent respiratory papillomatosis (RRP). PGEN achieved profitability in Q2 2026 with PAPZIMEOS revenues doubling quarter-over-quarter to $53.1 million and secured seven years of U.S. market exclusivity. Potential European approval of PAPZIMEOS and expansion of the AdenoVerse Immunotherapy platform, notably PRGN-2009, could unlock significant new market opportunities. Key catalysts include EMA review of PRGN-2012 and PRGN-2009 data updates by the end of 2026, with break-even cash flow targeted by year-end. Read the full article on Seeking Alpha
AdenoVerse Platform And First-Line RRP Therapy Will Shape Powerful Long-Term Earnings Potential
Catalysts About Precigen Precigen is a biotechnology company focused on developing and commercializing immunotherapies, including PAPZIMEOS for adults with recurrent respiratory papillomatosis and pipeline programs such as PRGN-2009 that use its AdenoVerse platform. What are the underlying business or industry changes driving this perspective?
PGEN: Orphan Exclusivity And Early RRP Uptake Will Drive Future Upside
Analysts have lifted the Precigen fair value estimate from $12.45 to $14.50, citing higher Street price targets attributed to Papzimeos sales that have exceeded guidance and recent FDA orphan-drug exclusivity for the therapy. Analyst Commentary Recent Street research on Precigen centers on Papzimeos launch execution and the impact of FDA orphan-drug exclusivity on the company’s revenue potential and valuation framework.PGEN: Orphan Exclusivity And Durable RRP Data Will Drive Future Upside
Analysts have raised their fair value estimate for Precigen from $8.50 to $12.45, citing higher price targets tied to Papzimeo’s orphan-drug exclusivity, stronger-than-guided launch traction, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Precigen has focused on the implications of Papzimeo’s launch performance and the orphan-drug exclusivity decision, with several price targets adjusted to reflect these updates.Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win
Precigen (PGEN) is back in focus after the FDA granted orphan drug exclusivity to PAPZIMEOS for adult recurrent respiratory papillomatosis, limiting similar competing therapies for seven years and defining a clearer commercial runway. See our latest analysis for Precigen. The FDA decision comes after a period of strong momentum for Precigen, with the share price delivering a 46.95% 3 month share price return and a very large 1 year total shareholder return. However, the 5 year total...Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement
Summary BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better. PRGN-3006 is an UltraCAR-T being developed to target patients with Acute Myeloid Leukemia; PRGN-3008 is an UltraCAR-T targeting patients with CD19 solid tumors and autoimmune disorders. Read the full article on Seeking AlphaPrecigen: Successful Proof Of Platform, But Cash Worries Remain
Summary Precigen's lead asset, PRGN-2012, shows promising results in treating Recurrent Respiratory Papillomatosis, achieving a 51% complete response rate and reducing surgical interventions. Financially, Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. The company is prioritizing PRGN-2012's development, restructuring operations, and cutting 20% of its workforce to extend its cash runway. Despite financial risks, Precigen's proven platforms and promising data make it a potential worthwhile investment, pending resolution of cash issues. Read the full article on Seeking AlphaWe're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$337m |
| Mar 31 2026 | n/a | n/a | -US$383m |
| Dec 31 2025 | US$5m | US$1m | -US$430m |
| Sep 30 2025 | n/a | n/a | -US$426m |
| Jun 30 2025 | n/a | n/a | -US$124m |
| Mar 31 2025 | n/a | n/a | -US$157m |
| Dec 31 2024 | US$5m | US$1m | -US$126m |
| Sep 30 2024 | n/a | n/a | -US$140m |
| Jun 30 2024 | n/a | n/a | -US$135m |
| Mar 31 2024 | n/a | n/a | -US$97m |
| Dec 31 2023 | US$4m | US$1m | -US$96m |
| Sep 30 2023 | n/a | n/a | -US$85m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$79m |
| Dec 31 2022 | US$3m | US$1m | -US$80m |
| Sep 30 2022 | n/a | n/a | -US$84m |
| Jun 30 2022 | n/a | n/a | -US$103m |
| Mar 31 2022 | n/a | n/a | -US$108m |
| Dec 31 2021 | US$3m | US$1m | -US$111m |
| Sep 30 2021 | n/a | n/a | -US$124m |
| Jun 30 2021 | n/a | n/a | -US$125m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | US$20m | US$1m | -US$104m |
| Sep 30 2020 | n/a | n/a | -US$100m |
| Jun 30 2020 | n/a | n/a | -US$122m |
| Mar 31 2020 | n/a | n/a | -US$138m |
| Dec 31 2019 | US$1m | US$500k | -US$169m |
Compensazione vs Mercato: La retribuzione totale di Helen ($USD 5.35M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 6.98M ).
Compensazione vs guadagni: La retribuzione di Helen è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Helen Sabzevari (64 yo)
Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intre...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 18.5yrs | US$600.00k | 3.74% $ 96.9m | |
| President | 6.6yrs | US$5.35m | 1.05% $ 27.2m | |
| Chief Financial Officer | 4.8yrs | US$1.49m | 0.071% $ 1.8m | |
| Chief Operating Officer | 6.5yrs | US$1.56m | 0.13% $ 3.4m | |
| Chief Legal Officer & Corporate Secretary | 15.6yrs | US$1.43m | 0.21% $ 5.5m | |
| Chief Commercial Officer | 2.1yrs | US$1.23m | 0.039% $ 1.0m | |
| VP & Head of Investor Relations | 8.6yrs | Nessun dato | Nessun dato | |
| Senior VP & Head of Research | no data | Nessun dato | Nessun dato | |
| Senior VP & Head of CMC | no data | Nessun dato | Nessun dato | |
| Senior VP & Head of Clinical Operations and Regulatory Affairs | 3.2yrs | Nessun dato | Nessun dato | |
| Chief Executive Officer of MBP Titan LLC | 7.6yrs | Nessun dato | Nessun dato |
Gestione esperta: Il team dirigenziale di PGEN è esperto e expertise (durata media dell'incarico 6.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 18.5yrs | US$600.00k | 3.74% $ 96.9m | |
| President | 6.2yrs | US$5.35m | 1.05% $ 27.2m | |
| Independent Director | 14.8yrs | US$319.00k | 0.056% $ 1.5m | |
| Independent Director | 10.2yrs | US$313.00k | 0.35% $ 9.0m | |
| Independent Director | 18.5yrs | US$312.50k | 0.22% $ 5.7m | |
| Lead Independent Director | 12.3yrs | US$312.50k | 0.19% $ 5.0m | |
| Independent Director | 18.5yrs | US$300.00k | 0.34% $ 8.9m | |
| Independent Director | 2.1yrs | US$306.50k | 0.085% $ 2.2m | |
| Independent Director | 9.3yrs | US$313.00k | 0.19% $ 4.8m |
Consiglio di amministrazione esperto: Il consiglio di amministrazione di PGEN è composto da personale esperto e esperto (durata media dell'incarico 12.3 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/10 05:39 |
| Prezzo dell'azione a fine giornata | 2026/08/10 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Precigen, Inc. è coperta da 10 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Ying Huang | Barclays |
| Derik de Bruin | BofA Global Research |
| Justin Walsh | B. Riley Securities, Inc. |